ESTRO 2024 - Abstract Book

S518

Clinical - Breast

ESTRO 2024

Patients receiving radical breast radiotherapy in February 2023 at a tertiary UK centre were identified from electronic patient records. In addition to the main hospital site, there are three satellite centres which allow patients to have radiotherapy delivered closer to home. Treatment factors including type of breast surgery, type of axillary surgery, use of chemotherapy, tumour bed boost, regional nodal irradiation, fractionation schedule, location of radiotherapy delivery (main or satellite centre) were extracted. Statistical analysis was conducted using R. Statistical significance for categorical variables was evaluated using chi square test, and for continuous variables with t-test, at significance level <0.05.

Results:

193 patients were identified. 100 (51.8%) were recorded as having attended the breast exercise physiotherapy class. 87 (45%) were treated at the main hospital site. 103 (53.3%) were treated with 26 Gy in five fractions, 90 were treated with 40 Gy in 15 fractions of which 46 (23.8%) received a sequential 12 Gy in four fraction tumour bed boost. 31 (16.0%) patients received treatment to the supraclavicular fossa. 88 (45.6%) received chemotherapy. 145 (75.1%) had sentinel lymph node biopsy (SLNB), 39 (20.2%) had axillary lymph node dissection (ALND) and 9 (4.7%) had no axillary surgery. 162 (83.9%) had wide local excision, 30 (15.5%) had mastectomy. 4 (2.1%) required an interpreter. 32.2% of patients receiving radiotherapy at main site attended the physiotherapy class, compared with 67.9% treated at satellite centres (p = <0.00001), see figure 1. There was no significant difference in the proportion of patients attending the physiotherapy class by the type of axillary surgery, breast surgery, fractionation schedule, use of chemotherapy, boost, supraclavicular fossa field or age category. Table 1 shows the proportions of those attending the class in different treatment groups.